Review Article

Right Ventricular Remodeling and Dysfunction in Obstructive Sleep Apnea: A Systematic Review of the Literature and Meta-Analysis

Abdirashit Maripov,^{1,2} Argen Mamazhakypov,^{1,3} Meerim Sartmyrzaeva,^{1,2} Almaz Akunov,^{1,2} Kubatbek Muratali uulu,^{1,2} Melis Duishobaev,^{1,2} Meerim Cholponbaeva,^{1,2} Akylbek Sydykov,^{1,3} and Akpay Sarybaev^{1,2}

¹Department of Mountain and Sleep Medicine and Pulmonary Hypertension, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

²*Kyrgyz-Indian Mountain Biomedical Research Center, Bishkek, Kyrgyzstan*

³Department of Internal Medicine, University of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University of Giessen, Giessen, Germany

Correspondence should be addressed to Akpay Sarybaev; ak_sar777@mail.ru

Received 29 January 2017; Accepted 21 May 2017; Published 26 July 2017

Academic Editor: R. Andrew Mcivor

Copyright © 2017 Abdirashit Maripov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Recent studies have reported that obstructive sleep apnea (OSA) patients present alterations in right ventricular (RV) structure and function. However, large randomized controlled trials evaluating the impact of OSA on the right ventricle are lacking. *Methods*. A comprehensive electronic database (PubMed, Web of Science, and Google Scholar) and reference search up to October 30, 2016, was performed. A systematic review and meta-analysis were performed to assess RV structure and function in OSA patients based on conventional echocardiography and tissue Doppler imaging. *Results*. Twenty-five studies with 1,503 OSA patients and 796 controls were included in this study. OSA patients exhibited an increase in RV internal diameter (weighted mean difference (WMD) (95% confidence intervals (CIs)) 2.49 (1.62 to 3.37); p = 0.000) and RV wall thickness (WMD (95% CIs) 0.82 (0.51 to 1.13); p = 0.000). Furthermore, OSA patients had a significantly elevated RV myocardial performance index (WMD (95% CI) 0.08 (0.06 to 0.10); p = 0.000), decreased RV S' (WMD (95% CI) -0.95 (-1.59 to -0.32); p = 0.003), tricuspid annular plane systolic excursion (WMD (95% CI) -1.76 (-2.73 to -0.78); p = 0.000), and RV fractional area change (WMD (95% CI) -3.16 (-5.60 to -0.73); p = 0.011). *Conclusion*. OSA patients display RV dilatation, increased wall thickening, and altered RV function.

1. Introduction

Obstructive sleep apnea (OSA) is characterized by repetitive episodes of complete and/or partial interruption of the respiratory airflow during sleep, leading to oxygen desaturation and chronic intermittent hypoxia. OSA is highly prevalent in the general population, affecting at least 9–15% of middle-aged adults [1, 2]. OSA represents a growing healthcare problem, as it has been increasingly implicated in the causation or promotion of various cardiovascular diseases [3]. Earlier reports have demonstrated increases in pulmonary artery pressure (PAP) during sleep, which suggested the development of sustained pulmonary hypertension in patients with OSA [4, 5]. Indeed, studies have shown that daytime pulmonary hypertension occurs in 20% to 40% of patients with OSA and concomitant pulmonary or heart disease [6–8]. Moreover, permanent pulmonary hypertension may also develop in OSA patients in the absence of other known cardiopulmonary disorders [9, 10]. Although pulmonary hypertension in OSA is usually mild to moderate, it confers functional limitations and a poor prognosis [11]. Furthermore, pulmonary hypertension in OSA patients can lead to the development of right ventricular (RV) hypertrophy and dysfunction. However, radionuclide ventriculography studies have demonstrated that RV dysfunction may develop independently of pulmonary hypertension in these patients [12]. Importantly, alterations in RV structure and function have been shown to predict the clinical outcomes in cardiopulmonary diseases [13, 14].

Echocardiography is a noninvasive, low-cost, timesaving, and accurate tool for assessments of alterations in cardiac structure and function. Therefore, in clinical practice, ventricular structure and function are commonly assessed using echocardiography. In recent years, several echocardiographic studies have reported that OSA patients frequently present structural and functional alterations of the right ventricle [16-21, 23, 24, 26, 29, 31-36, 38]. However, since most of the studies were small and assessed few echocardiographic parameters, the outcomes from these studies have been inconsistent. Because large randomized controlled trials directly evaluating the impact of OSA on the structural and functional alterations of the right ventricle are lacking, we aimed to perform a systematic review of the literature and meta-analysis of studies based on the conventional echocardiographic assessment of RV structure and function in OSA patients.

2. Methods

2.1. Search Strategy and Literature Screening. A systematic literature review was conducted using electronic databases (PubMed, Web of Science, and Google Scholar). All databases were searched up to October 30, 2016, using the following terms: "obstructive sleep apnea", "sleep-disordered breathing", "right ventricular function", "right ventricular dysfunction", "right heart failure", and "echocardiography". In addition, we reviewed the reference lists from all relevant articles to find other potential sources. The process of selecting studies is outlined in Figure 1.

Articles were first screened by title and abstract, and reviews, guidelines, letters, case reports, editorials, and in vitro and animal studies were excluded. In a second screen, the following criteria were used to identify potentially suitable studies: (1) studies were written fully in English; (2) enrolled subjects were adults, above 18 years old; (3) OSA patients did not have major comorbidities; (4) the study included a control group; (5) OSA was diagnosed by polysomnography; (6) the study reported at least one of the measures of RV function and RV remodeling. After the abovementioned screening, the authors obtained the full-text articles and read them carefully and independently.

2.2. Data Extraction and Processing. Two independent reviewers (Abdirashit Maripov and Argen Mamazhakypov) screened and extracted data from full-text articles using standardized data extraction sheets. The following study characteristics were extracted from the articles: first author, publication year, country, numbers of patients and healthy controls, mean age, sample size, body mass index (BMI), mean apnea-hypopnea index (AHI), PAP values, and RV



FIGURE 1: Flow chart of the literature search and study selection.

morphology and function parameters. The main echocardiographic parameters involved in the assessment of RV morphology and function were RV internal diameter (RVID), RV wall thickness (RVWT), RV fractional area change (FAC), RV myocardial performance index (MPI), pulsed-wave tissue Doppler imaging- (TDI-) derived velocity of the tricuspid annular systolic motion (RV S'), and tricuspid annular plane systolic excursion (TAPSE). In cases of conflicting evaluations, disagreements were resolved through discussion between the authors.

2.3. Data Analysis. Several studies stratified patients based on OSA severity (mild, moderate, or severe) and reported grouped RV function data within each stratum. In those cases, because they represented independent samples, we considered each stratum as a separate substudy. All analyses were calculated using the statistical package Stata, version 14.1 (StataCorp, College Station, TX, USA) with the random-effects model. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated using a random-effects model. Fisher's *z* test was used to determine the statistical significance of the pooled WMDs. Cochran's χ^2 test and the I^2 statistic were used to assess between-study heterogeneity. Heterogeneity was considered statistically significant at p < 0.10 and $I^2 > 50\%$.

3. Results

3.1. Literature Search. Using electronic searches of the databases, 546 citations were obtained. We screened the studies through title and abstract review and removed duplicates, reviews, meta-analyses, nonhuman studies, case reports, and guidelines. Two hundred and five studies underwent full-text review. After full-text review, 180 studies were excluded according to the inclusion and exclusion criteria described above. A total of 25 studies with 1,503 OSA patients and 796

Canadian Respiratory Journal

Study	Year					WMD (95% CI)	% weight
Hanly et al.	1992		•			-0.40 (-2.85, 2.05)	3.66
Guidry et al.	2001					-0.20 (-0.38, -0.02)	5.14
Dursunoğlu et al. (1)	2005					0.80 (-1.79, 3.39)	3.54
Dursunoğlu et al. (2-3)	2005					1.80 (0.27, 3.33)	4.44
Verbraecken et al.	2005			•		7.00 (4.96, 9.04)	4.02
Shivalkar et al.	2006			•		7.00 (4.96, 9.04)	4.02
Kasikcioglu et al.	2007			<u> </u>		4.00 (1.37, 6.63)	3.51
Otto et al.	2007		-			1.00 (0.38, 1.62)	5.02
Bayram et al.	2008					2.20 (0.66, 3.74)	4.44
Kepez et al. (1-2)	2009		-			0.40 (-0.55, 1.35)	4.85
Kepez et al. (3)	2009		→			0.00 (-0.84, 0.84)	4.91
Tugcu et al.	2010					1.00 (-0.38, 2.38)	4.56
Yang et al. (1)	2012		*			0.02 (-0.52, 0.56)	5.05
Yang et al. (2)	2012					3.10 (2.52, 3.68)	5.03
Yang et al. (3)	2012			•		4.85 (4.04, 5.66)	4.93
Araz et al.	2014					13.20 (11.60, 14.80)	4.38
D'Andrea et al.	2016					2.50 (0.93, 4.07)	4.41
Li et al. (1)	2016		+			0.20 (-0.28, 0.68)	5.07
Li et al. (2)	2016		•			0.79 (0.30, 1.28)	5.07
Li et al. (3)	2016		•			0.67 (0.09, 1.25)	5.04
Ozkececi et al.	2016					1.90 (0.28, 3.52)	4.37
Altiparmak et al.	2016			•		5.40 (3.99, 6.81)	4.54
Overall ($I^2 = 96.8\%$, $p =$	0.000)		\Diamond			2.50 (1.62, 3.37)	100.00
Note. Weights are from ra	ndom-effects analysis						
	-10		0		15		
	-	RVID decreased		RVID increased	-		

FIGURE 2: Forest plot of the differences in right ventricular internal diameter (RVID) at diastole between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

healthy control participants were included in this study. The flow diagram of the selection process is shown in Figure 1.

3.2. Characteristics of the Included Studies. The publication years of the involved studies ranged from 1992 to 2016. The majority of the studies (12 studies, 48%) were conducted in Turkey; 4 studies were conducted in North America (USA and Canada), 3 studies were conducted in China, and 6 studies were conducted in Europe (Belgium, Germany, Poland, and Italy). In all studies, OSA was diagnosed by polysomnography. In the control groups, OSA was excluded based on polysomnography in 18 studies. In 7 studies, healthy control subjects were enrolled based on the absence of clinical symptoms of sleepiness [17, 19, 20, 25, 29, 31] or cardiovascular diseases [39]. For the assessment of RV remodeling, 16 studies (64%) used RVID and 9 studies (36%) used RVWT. For the assessment of RV function, 11 studies (44%) used TAPSE, 14 studies (56%) used RV MPI, 6 studies (24%) used RV FAC, and 14 studies (48%) used RV S'. The main characteristics of the studies in this systematic review are listed in Table 1.

3.3. Meta-Analysis. We performed a meta-analysis for changes in RV structure and function. Figures 2 and 3 show the changes in RVWT and RVID. Changes in RV MPI, RV S', TAPSE, and RV FAC are shown in Figures 4–7. Table 2 shows the summary data of all parameters of the RV structure and function determined by the meta-analysis. Heterogeneity was obvious in the assessment of the RV structure and function parameters, which could have been a result of differences in geographical location, participants' ages, severities of disease, and RV remodeling.

3.3.1. RV Remodeling. To evaluate RV structure, RVID and RVWT were assessed. Changes in RVID were reported in 16 studies (22 strata) involving 902 OSA patients and 596 control subjects. The meta-analysis showed that the RVID in patients with OSA was significantly larger compared to the

apnea; ESS: Epv	vorth Sleepin	iess Scale; P	SG: polysomn	ography; AHI: 4	apnea-hypopn	ea index; PAP: pulmonary artery pre	ssure; N/A: not ap	plicable.		aver we way
Study	Year of publication	Country	Number of participants	Mean (SD) age (years)	BMI (kg/m ²)	OSA diagnosis (methods; criteria)/control group determination	Mean (SD) ESS score	Mean (SD) AHI	Mean (SD) PAP (mmHg)	RV remodeling and dysfunction measures
Hanly et al. [15]	1992	Canada	31 (OSA) 20 (control)	50(12.3) 48(8.8)	32.8 (7.2) 26.2 (3.2)	PSG; AHI < 5 events/h PSG; AHI \geq 5 events/h	N/A N/A	49 (25.5) 2.7 (1.6)	N/A N/A	RVID, RVWT
Guidry et al. [16]	2001	USA	90 (OSA) 90 (control)	60 (9) 61 (9)	32 (5) 28 (4)	PSG; RDI > 90th percentile PSG; RDI < 50th percentile	N/A N/A	42.0 (15.3) (RDI) 4.6 (2.6) (RDI)	N/A N/A	RV FAC, RVWT, RVID
Verbraecken et al. [17]	2005	Belgium	43 (OSA) 40 (control)	55 (11) 50 (16)	31.6(5.4) 26.4(2.3)	PSG; AHI > 20 events/h ESS score = 0 (all)	N/A N/A	42 (24) N/A	N/A N/A	RVID, RV MPI, RV S'
Dursunoğlu et al. [18]	2005	Turkey	11 (mild OSA) 18 (moderate- to-severe OSA)	46.0(5.6) 46.5(4.9)	30.4(4.0) $30.6(4)$	PSG; AHI > 5-<15 events/h PSG; AHI ≥ 15 events/h	N/A N/A	25.3 (2.6) 50.1 (11.6)	N/A N/A	RVWT, RVID, RV MPI
			20 (control)	43.5 (6)	29.3 (2.4)	PSG; AHI < 5 events/h	N/A	5.2 (2.8)	N/A	
Shivalkar et al. [19]	2006	Belgium	43 (OSA) 40 (control)	55 (11) 50 (16)	31.6(5.4) 26.4(2.3)	PSG; AHI ≥ 5 events/h ESS score = 0 (all)	N/A N/A	N/A N/A	32 (10) 22 (8)	RVID, RV MPI, RV S'
Kasikcioglu et al. [20]	2007	Turkey	10 (OSA) 10 (control)	42 (6) 45 (9)	30.6 (3.2) 27.7 (2.6)	PSG: AHI > 30 events/h Healthy males	N/A N/A	43.8 (11.7) 2.1 (1.0)	N/A N/A	RVID, RV S'
-			15 (mild OSA). 36	59 (14)	33 (6)	PSG; AHI > 5-< 14 events/h	N/A	9.2 (2.9)	33.6 (12.7)	
komero-Corral et al. [21]	2007	USA	(moderate- to-severe OSA)	63 (14)	33 (5)	PSG; AHI ≥ 15 events/h	N/A	34.9 (17.9)	33.9 (8.4)	RV MPI, RV FAC
			26 (control)	55 (15)	31 (6)	PSG; AHI < 5 events/h	N/A	1.7(1.4)	34.0(9.4)	
Otto et al. [22]	2007	USA	23 (OSA) 18 (control)	45 (3) 45 (2)	33.7 (0.8) 32.3 (0.9)	PSG; AHI ≥ 5 events/h PSG; AHI < 5 events/h	N/A N/A	50 (7) 2 (0.4)	N/A N/A	RVID, RV S'
Tavil et al. [23]	2007	Turkey	20 (OSA) 21 (control)	50 (7) 49 (5)	30 (7) 29 (6)	PSG; AHI ≥ 5 events/h PSG; AHI < 5 events/h	N/A N/A	31 (29) 2 (2)	N/A N/A	TAPSE, RV S', RV MPI
Bayram et al. [24]	2008	Turkey	28 (OSA) 18 (control)	$44.8\ (10.5)$ $41.9\ (11.5)$	29.7 (5.3) 27.9 (2.7)	PSG; AHI ≥ 15 events/h PSG; AHI < 5 events/h	N/A N/A	62.3 (21.6) 2.6 (0.8)	N/A N/A	RVID, RV S',

TABLE I: Characteristics of the included studies. RVID: right ventricular basal diameter measured at end-diastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep

	RV remodeling and dysfunction measures		RVID, RV S'		RVWT, TAPSE,	RV MPI, RV S'	RVWT, RVID, TABET BU C'	IAPSE, KV S		RVID. RVWT. RV	MPI,				RV MPI, TAPSE			TADEF BV MDI	TALOE, NV WIFT	DV/ MDI	T TTAT AN
	Mean (SD) PAP (mmHg)	N/A	N/A	N/A	28.20 (4.66)	24.73 (2.49)	26.6 (3.1)	24.1 (2.3)	28 (6)	38 (6)		55 (11)	22 (5)	27.62 (4.32)	29.78 (4.24)	32.06 (3.71)	25.61 (5.43)	22.0 (12.6)	17.3 (11.9)	21.8 (5.9)	22.1 (4.4)
	Mean (SD) AHI	15.0 (13.0)	46.0 (42.0)	N/A	38.84 (21.80)	1.46(0.68)	40 (22)	2 (1)	JD (E C)	(0·C) N7			2.9 (2)	10.73 (2.57)	20.52 (2.60)	58.1 (16.27)	N/A	35.9 (28.4)	2.3 (1.3)	N/A	N/A
	Mean (SD) ESS score	N/A	N/A	N/A	19.37 (4.30)	2.60(2.29)	N/A	N/A	N/A	N/A		N/A	N/A	N/A	N/A	N/A	N/A	10.4 (5.2)	7.9 (5.6)	9.17(5.10)	0.26 (0.54)
TABLE 1: Continued.	OSA diagnosis (methods; criteria)/control group determination	PSG; AHI > 5-< 30 events/h	PSG; AHI ≥ 30 events/h	Absence of symptoms of sleep-related disorders	PSG; AHI \geq 15 events/h, ESS score \geq 10	PSG; AHI < 5 events/h, ESS score < 10	PSG; AHI \geq 15 events/h, ESS score \geq 10	PSG; AHI < 5 events/h, ESS score < 10	PSG; AHI 5–15 events/h, SpO ₂ nadir 85–89%	PSG; AHI 15–30 events/h, SpO ₂ nadir	80-84% BCC: ATT > 30 accounts /b C=0 and dim	rəG; Ahl > 30 events/n, əpO2 natif <80%	PSG; AHI < 5 events/h	PSG; AHI > 5-<15 events/h	PSG; AHI > 15-< 30 events/h	$PSG; AHI \ge 30 \text{ events/h}$	ESS score < 10	PSG; AHI < 5 events/h	PSG ; $AHI \ge 5 \text{ events/h}$	PSG ; $AHI \ge 15$ events/h	ESS score < 10
Τ	BMI (kg/m ²)	28.4 (3.4)	31.5 (4.9)	27.7 (4.0)	31.38 (4.97)	30.10(3.65)	31.1(5.1)	29.6 (3.6)	0720 (E 74)	(#1.6) 66.12			26.32 (4.57)	28.68 (3.44)	29.05 (2.26)	29.80 (2.38)	26.35 (4.14)	31.1 (5.8)	30.1(5.5)	34.8 (7.8)	25.8 (1.7)
	Mean (SD) age (years)	48.8 (8.2)	48.6 (9.2)	46.1 (8.7)	56 (12)	54(10)	54(10)	54 (10)	F 0 1 (0 1)	(7.0) 4.00			59.8 (1.1)	46.95~(6.4)	46.79 (5)	46.68 (7.6)	45.38(4.5)	61.7 (12.4)	55.7 (15.8)	53.6 (7.1)	53.7 (6.5)
	Number of participants	45 (mild-to- moderate OSA)	40 (severe OSA)	30 (control)	41 (OSA)	30 (control)	27 (OSA)	26 (control)	77 (mild OSA)	81 (moderate	(Nod)	02A) OSA)	75 (control)	20 (mild OSA)	19 (moderate OSA)	19 (severe OSA)	21 (control)	154 (OSA)	29 (control)	23 (OSA)	23 (control)
	Country		Turkey		Turkev	lowing	Turkey			i	China				Turkey			Germany	COLLIGEN	Turben	tutve
	Year of publication		2009		2009	0001	2010				2012				2012			2017	7107	2013	CT07
	Study		Kepez et al. [25]		There at al [36]	Tugun et al. [20]	Tugcu et al. [27]	[]			Yang et al. [28]				Altekin et al. [29]			Hammerstingl et	al. [30]	Ç	Uztuna et al. Uztuna

Study	Year of publication	Country	Number of participants	Mean (SD) age (years)	BMI (kg/m ²)	OSA diagnosis (methods; criteria)/control group determination	Mean (SD) ESS score	Mean (SD) AHI	Mean (SD) PAP (mmHg)	RV remodeling and dysfunction measures
Araz et al. [32]	2014	Turkey	67 (OSA) 31 (control)	49.7 (12.7) 49.8 (10.9)	34.6 (8.3) 29.5 (7.3)	PSG; AHI ≥ 5 events/h PSG; AHI < 5 events/h	10 (4) 3 (2)	52 (6) 1.5 (1.4)	41.2 (12.9) 25.3 (7.5)	RVID
			10 (mild OSA)	47.9 (10.3)	26.9 (5.8)	PSG; AHI > 5-<15 events/h	N/A	7.1 (1.9)	25 (6)	
Vitarelli et al.	2015	Italy	8 (moderate OSA)	47.6 (9.1)	27.4 (5.5)	PSG; AHI > 15-< 30 events/h	N/A	19.8 (2.7)	35 (11)	TAPSE, RV MPI,
[cc]			19 (severe OSA)	48.1 (10.2)	28.2 (6.3)	PSG; AHI ≥ 30 events/h	N/A	58.9 (9.1)	46 (11)	RV FAC, RV S'
			30 (control)	46.2 (13.4)	26.4(4.3)	PSG; AHI < 5 events/h	N/A	3.8(1.4)	22 (3)	
Ozkececi et al. [34]	2016	Turkey	30 (OSA) 60 (control)	49.6(11.7) 46.4(14)	31.6 (5.8) 29.3 (4.8)	PSG;AHI ≥ 5 events/h PSG; AHI < 5 events/h	N/A N/A	24.5 (6–98) 1 (1–4)	22.4 (8.9) 12.7 (7.5)	RVID, RV MPI, RV S', TAPSE
Altiparmak et al. [35]	2016	Turkey	52 (OSA) 42 (control)	49(10) $46(7)$	26.5(2.1) 25.8(3.3)	PSG; AHI ≥ 5 events/h PSG; AHI < 5 events/h	N/A N/A	N/A N/A	32.4 (7) 21.6 (4.3)	RVID, RVWT, TAPSE, RV S'
			24 (mild OSA)	47.3 (6.1)	26.40 (3.12)	PSG; AHI > 5-<15 events/h	N/A	12.72 (2.03)	N/A	
Li et al. [36]	2016	China	25 (moderate OSA)	47.9 (7.9)	26.83 (3.55)	PSG; AHI > 15-< 30 events/h	N/A	24.01 (3.56)	N/A	RVWT, RVID,
			20 (severe OSA)	48.5(5.4)	27.97 (3.59)	PSG; AHI ≥ 30 events/h	N/A	40.78 (5.02)	N/A	IAPSE, KV FAC
			31 (control)	46.8 (5.4)	24.86 (2.78)	PSG; AHI < 5 events/h	N/A	1.72 (1.01)	N/A	
			45 (mild OSA)		N/A	PSG; AHI > 5-<15 events/h	N/A	N/A	N/A	
Dobrowolski et	2000	Daland	27 (moderate OSA)	47.5 (10.5) All	N/A	PSG; AHI > 15-< 30 events/h	N/A	N/A	N/A	TAPSE, RV FAC,
al. [37]	0107	rolallu	40 (severe OSA)		N/A	PSG; AHI ≥ 30 events/h	N/A	N/A	N/A	RV S'
			43 (control)		N/A	PSG; AHI < 5 events/h	N/A	N/A	N/A	
			21 (mild OSA)	52.8 (11.9)	29.6 (9.1)	PSG; AHI > 5-<15 events/h	N/A	N/A	35.7 (6.1)	
Zhou et al. [38]	2016	China	19 (moderate OSA)	55.7 (12.4)	35.2 (10.1)	PSG; AHI > 15-< 30 events/h	N/A	N/A	33.4 (5.8)	RV FAC RV MPI
			23 (severe OSA)	50.2 (12.1)	39.2 (9.8)	PSG; AHI ≥ 30 events/h	N/A	N/A	18.7 (6.9)	
			19 (control)	52.0 (10.8)	24.2 (3.7)	PSG; AHI < 5 events/h	N/A	N/A	16.7 (6.2)	
D'Andrea et al.			55 (OSA)	67.8 (11.2)	33.6 (6.6)	$PSG; AHI \ge 5 events/h$	N/A	35.1(15.4)	35.8(14.4)	TWID RVWT
[39]	2016	Italy	45 (control)	65.9 (12.3)	28.7 (3.6)	Absence of cardiovascular, structural, and functional abnormalities	N/A	N/A	24.8 (11.3)	TAPSE

TABLE 1: Continued.

6

Canadian Respiratory Journal

Canadian Respiratory Journal

Study	Year				WMD (95% CI)	% weight
Hanly et al.	1992				0.00 (-0.64, 0.64)	5.56
Guidry et al.	2001		٠		1.00 (0.94, 1.06)	7.23
Dursunoğlu et al. (1)	2005				0.20 (-0.51, 0.91)	5.26
Dursunoğlu et al. (2-3)	2005				0.40 (-0.24, 1.04)	5.53
Tugcu et al.	2009				0.92 (0.63, 1.21)	6.83
Tugcu et al.	2010	-	•		0.30 (0.08, 0.52)	7.01
Yang et al. (1)	2012				0.57 (0.23, 0.91)	6.67
Yang et al. (2)	2012		•		2.32 (1.81, 2.83)	6.07
Yang et al. (3)	2012				3.36 (2.88, 3.84)	6.17
Vitarelli et al. (1)	2015		⊢ ¦		0.06 (-0.33, 0.45)	6.51
Vitarelli et al. (2)	2015	_	•		0.37 (-0.03, 0.77)	6.48
Vitarelli et al. (3)	2015				1.65 (1.31, 1.99)	6.66
Li et al. (1)	2016	-	►		0.16 (0.02, 0.30)	7.15
Li et al. (2)	2016		-		0.61 (0.34, 0.88)	6.88
Li et al. (3)	2016				0.72 (0.39, 1.05)	6.70
D'Andrea et al.	2016				0.20 (-1.06, 1.46)	3.30
Overall ($I^2 = 95.6\%, p = 0$.000)		$\langle \rangle$		0.82 (0.51, 1.13)	100.00
Note. Weights are from ran	dom-effects analysis	;				
	-4	1 0		4		
		RVWT decreased	RVWT increased			

FIGURE 3: Forest plot of the differences in right ventricular free wall thickness (RVWT) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

TABLE 2: Results of the meta-analysis comparing OSA patients and healthy controls. RVID: right ventricular basal diameter measured at enddiastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

Echocardiographic	Number of	OSA/control	WMD (95% CI)	to value	Stu	dy heteroge	neity	Egger's test p
parameters	studies	Contrecinitor	WWD (95% CI)	<i>p</i> value	I^2	χ^2	<i>p</i> value	value
RVID	16	902/596	2.49 (1.62, 3.37)	0.000	96.8%	647.61	0.000	0.001
RVWT	9	579/397	0.82 (0.51, 1.13)	0.000	95.6%	344.56	0.000	0.671
RV MPI	14	864/434	0.08 (0.06, 0.10)	0.000	84.1%	157.39	0.000	0.150
RV S'	14	639/391	-0.95 (-1.59, -0.32)	0.003	88.4%	190.21	0.000	0.347
TAPSE	11	655/378	-1.76 (-2.73, -0.78)	0.000	89.3%	187.24	0.000	0.462
RV FAC	6	422/239	-3.16 (-5.60, -0.73)	0.011	80.2%	70.83	0.000	0.006

controls (WMD (95% CIs) 2.49 (1.62 to 3.37); p = 0.000; Figure 2). In addition, changes in RVWT were reported in 9 studies (16 strata) involving 579 patients with OSA and 379 control subjects. Patients with OSA had significantly increased RVWT compared to the controls (WMD (95% CIs) 0.82 (0.51 to 1.13); p = 0.000; Figure 3). *3.3.2. RV Function.* To evaluate RV function, RV MPI, RV S', TAPSE, and RV FAC were assessed. The most commonly reported RV functional parameters were RV MPI (14 studies, 26 strata, 864 patients with OSA and 434 control subjects) and RV S' (14 studies, 23 strata, 639 patients with OSA and 391 control subjects). The TAPSE was reported in 11

Study	Year				WMD (95% CI)	% weight
Dursunoğlu et al. (1)	2005		•		0.02 (-0.05, 0.09)	3.44
Dursunoğlu et al. (2-3)	2005			•	0.14 (0.05, 0.23)	2.69
Verbraecken et al.	2005		-		0.04 (0.02, 0.06)	5.35
Shivalkar et al.	2006		-	•	0.07 (0.05, 0.09)	5.28
Romero-Corral et al. (1)	2007	-	•		0.03 (-0.06, 0.12)	2.71
Romero-Corral et al. (2-3)	2007			•	0.14 (0.09, 0.19)	4.08
Tavil et al.	2007				0.10 (0.06, 0.14)	4.73
Tugcu et al.	2009			•	0.16 (0.11, 0.20)	4.42
Altekin et al. (1)	2012		•		0.03 (-0.03, 0.09)	3.98
Altekin et al. (2)	2012		-	•	0.10 (0.05, 0.15)	4.08
Altekin et al. (3)	2012			•	0.13 (0.07, 0.19)	3.67
Hammerstingl et al. (1)	2012		•		0.00 (-0.10, 0.10)	2.53
Hammerstingl et al. (2)	2012				0.10 (-0.01, 0.21)	2.11
Hammerstingl et al. (3)	2012		•		0.00 (-0.09, 0.09)	2.78
Yang et al. (1)	2012				0.03 (0.00, 0.06)	5.07
Yang et al. (2)	2012		-	•	0.08 (0.06, 0.10)	5.28
Yang et al. (3)	2012				0.17 (0.14, 0.20)	4.84
Öztuna et al.	2013			•	0.07 (0.03, 0.11)	4.64
Vitarelli et al. (1)	2015		•	 	0.02 (-0.04, 0.08)	3.79
Vitarelli et al. (2)	2015			•	0.08 (0.01, 0.15)	3.29
Vitarelli et al. (3)	2015				0.24 (0.18, 0.30)	3.86
Ozkececi et al.	2016		•		-0.01 (-0.13, 0.12)	1.84
Zhou et al. (1)	2016		•	- 1	0.01 (-0.05, 0.07)	3.70
Zhou et al. (2)	2016		-	•	0.14 (0.06, 0.22)	3.07
Zhou et al. (3)	2016			•	0.16 (0.09, 0.23)	3.38
Altiparmak et al.	2016		-		0.04 (0.02, 0.06)	5.38
Overall ($I^2 = 84.1\%$, $p = 0.000$))			\Rightarrow	0.08 (0.06, 0.10)	100.00
Note. Weights are from random	n-effects analysis					
	35		0		.35	
		RV MPI decreased		RV MPI increased		

FIGURE 4: Forest plot of the differences in right ventricular myocardial performance index (RV MPI) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

studies (21 strata, 655 patients with OSA and 378 control subjects), while 6 studies assessed the RV FAC (15 strata, 422 patients with OSA and 239 control subjects). The metaanalysis demonstrated that the RV MPI was significantly elevated in patients with OSA compared to the controls (WMD (95% CI) 0.08 (0.06 to 0.10); p = 0.000; Figure 4). We also found significant differences between the patients with OSA and controls for RV S' (WMD (95% CI) -0.95 (-1.59 to -0.32); p = 0.003; Figure 5). In addition, TAPSE (WMD (95% CI) -1.76 (-2.73 to -0.78); p = 0.000; Figure 6) and RV FAC (WMD (95% CI) -3.16 (-5.60 to -0.73); p = 0.011; Figure 7) were also significantly decreased in the patients with OSA compared to the controls.

4. Discussion

To our knowledge, this is the first meta-analysis to systematically evaluate changes in RV structure and function in OSA patients. In this meta-analysis, 25 case-control studies were included, with a total of 1,503 patients with OSA and 796 healthy controls. In the present study, we found that alterations in echocardiographic parameters of RV remodeling, including an increase in RVWT and RVID, were important features in OSA patients without major comorbidities. Furthermore, our meta-analysis demonstrated that, in these patients, conventional echocardiography and pulsed-wave TDI-derived parameters of RV function were significantly altered compared to the controls. We found significant heterogeneity between studies. However, heterogeneity is to be expected given the variety of studies conducted by different teams at various geographic locations, the variation in disease severity, and differences in the patient populations. In most studies, the investigators were blinded to the participants' study group status [15, 16, 21-27, 29, 31, 33-35, 38, 39]. In addition, interobserver agreement and intraobserver reproducibility were assessed in most of the studies [15, 16, 21, 23-25, 27, 29, 33, 36, 38, 39].



FIGURE 5: Forest plot of the differences in right ventricular annular systolic velocity (RV S') between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

Although cardiac magnetic resonance imaging is considered as the gold standard for morphological and functional assessment of the right ventricle, conventional echocardiography remains the first-resort imaging modality in routine clinical practice due to its low cost, simplicity, reproducibility noninvasive nature, safety, and lack of ionizing radiation [40, 41]. However, accurate evaluation of RV morphology and function remains challenging in clinical practice due to its complex geometric shape [42]. Nevertheless, echocardiography was performed according to the recommendations of the American Society of Echocardiography in all of the studies included in the current meta-analysis [42].

Conventional echocardiography and pulsed-wave TDI allow for the assessment of RV function by quantifying RV FAC, MPI, TAPSE, and RV S'. Several studies exploiting conventional echocardiography and tissue Doppler imaging have reported that OSA patients frequently present structural and functional alterations of the right ventricle [16–21, 23, 24, 26, 29, 31–36, 38]. In contrast, other studies did not reveal any

changes in RV morphology and function in OSA patients by the application of conventional echocardiography and TDI [15, 22, 25, 27, 30, 37, 39]. Importantly, novel techniques, including 2D and 3D speckle-tracking echocardiography, are very sensitive and can reveal alterations in RV morphology and performance in early disease stages when changes in the conventional echocardiographic parameters are not yet present [25, 27, 36, 39]. However, these sophisticated techniques require expertise and have not been extensively validated for the assessment of RV function.

Multiple mechanisms underlie alterations in RV morphology and function in OSA patients [43]. Numerous studies have reported permanent pulmonary hypertension in OSA patients. In this population, pulmonary hypertension is often associated with chronic obstructive pulmonary disease [6, 7]. In addition, OSA patients with pulmonary hypertension often have cardiac comorbidities, including hypertension and left ventricular dysfunction. However, permanent pulmonary hypertension may also develop in OSA patients

Study	Year				WMD (95% CI)	% weight
Tavil et al.	2007	_	•		-2.40 (-4.16, -0.64)	4.85
Tugcu et al.	2009		-		-4.17 (-5.43, -2.91)	5.26
Tugcu et al.	2010				-0.70 (-1.54, 0.14)	5.53
Altekin et al. (1)	2012	-	•		-2.46 (-3.70, -1.22)	5.28
Altekin et al. (2)	2012		-		-3.65 (-4.62, -2.68)	5.46
Altekin et al. (3)	2012				-5.34 (-6.33, -4.35)	5.44
Hammerstingl et al. (1)	2012				1.70 (-1.08, 4.48)	3.93
Hammerstingl et al. (2)	2012			_	0.70 (-2.22, 3.62)	3.81
Hammerstingl et al. (3)	2012		-		0.10 (-2.75, 2.95)	3.87
Vitarelli et al. (1)	2015				-2.00 (-4.84, 0.84)	3.88
Vitarelli et al. (2)	2015	•			-5.00 (-8.51, -1.49)	3.31
Vitarelli et al. (3)	2015	•			-7.00 (-9.80, -4.20)	3.91
Dobrowolski et al. (1)	2016				1.30 (-0.21, 2.81)	5.07
Dobrowolski et al. (2)	2016			_	1.40 (-0.79, 3.59)	4.47
Dobrowolski et al. (3)	2016			_	1.40 (-0.61, 3.41)	4.64
Li et al. (1)	2016				-0.62 (-1.63, 0.39)	5.43
Li et al. (2)	2016		-		-1.81 (-2.97, -0.65)	5.33
Li et al. (3)	2016				-5.54 (-6.85, -4.23)	5.22
Ozkececi et al.	2016				0.40 (-1.46, 2.26)	4.77
D'Andrea et al.	2016				-1.20 (-2.13, -0.27)	5.48
Altiparmak et al.	2016		•		-1.40 (-2.94, 0.14)	5.05
Overall ($I^2 = 89.3\%, p = 0$.000)		\Diamond		-1.76 (-2.74, -0.78)	100.00
Note. Weights are from ran	dom-effects analysis	;				
	-15		0		15	
		TAPSE decreased		TAPSE increased		

FIGURE 6: Forest plot of the differences in tricuspid annular plane systolic excursion (TAPSE) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

in the absence of other known cardiopulmonary disorders [9, 10]. Pulmonary hypertension in OSA patients can lead to the development of RV hypertrophy and dysfunction. Early studies have reported right heart failure in OSA patients that was associated with daytime hypoxemia due to underlying lung disease [44]. However, recent studies have demonstrated that RV function is impaired in OSA patients even after adjustments for potential confounders [12, 21, 27]. An independent effect of OSA on RV structure and performance was observed in a number of studies, showing a correlation between AHI and RV parameters, such as RV MPI [18, 21, 26], RV EF [12, 21], RV S' [17, 19, 23], RVID [17], RVWT [26], TAPSE [26, 29], and RV strain variables [27, 29, 30]. Another possible mechanism that could lead to RV dysfunction in OSA patients is the generation of negative intrathoracic pressure against an occluded airway, causing increased venous return and volume overload of the right ventricle during apnea periods [29, 45]. During RV hypertrophy, myocardial oxygen demands may increase,

leading to RV ischemia and dysfunction [43]. Additionally, OSA is much more common in obese individuals. It has been shown that isolated obesity in young adults is associated with subclinical abnormalities in RV structure and function, which are independent of the presence of OSA and its severity [46, 47].

5. Conclusions

The present study represents the first systematic review of the literature and meta-analysis to explore RV involvement in OSA patients. We concluded that OSA patients display increased RV wall thickening and dilatation along with impaired RV function.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Canadian Respiratory Journal



FIGURE 7: Forest plot of the differences in right ventricular fractional change (RV FAC) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

Authors' Contributions

Abdirashit Maripov, Argen Mamazhakypov, Almaz Akunov, Akylbek Sydykov, and Akpay Sarybaev participated in the conception and design of the paper. Abdirashit Maripov, Argen Mamazhakypov, Meerim Sartmyrzaeva, Kubatbek Muratali uulu, Melis Duishobaev, and Meerim Cholponbaeva contributed to the analysis and interpretation of the data and drafted the manuscript. Almaz Akunov, Akylbek Sydykov, and Akpay Sarybaev reviewed the manuscript and approved its final version.

References

- L. Ferini-Strambi, M. L. Fantini, and C. Castronovo, "Epidemiology of obstructive sleep apnea syndrome," *Minerva Medica*, vol. 95, no. 3, pp. 187–202, 2004.
- [2] E. S. Arnardottir, E. Bjornsdottir, K. A. Olafsdottir, B. Benediktsdottir, and T. Gislason, "Obstructive sleep apnoea in the general population: highly prevalent but minimal symptoms," *European Respiratory Journal*, vol. 47, no. 1, pp. 194–202, 2016.
- [3] E. A. Phillipson, "Sleep apnea a major public health problem," *New England Journal of Medicine*, vol. 328, no. 17, pp. 1271–1273, 1993.

- [4] G. Coccagna, M. Mantovani, F. Brignani, C. Parchi, and E. Lugaresi, "Continuous recording of the pulmonary and systemic arterial pressure during sleep in syndromes of hypersomnia with periodic breathing," *Bulletin De Physio-Pathologie Respiratoire*, vol. 8, no. 5, pp. 1159–1172, 1972.
- [5] A. G. Tilkian, C. Guilleminault, J. S. Schroeder, K. L. Lehrman, F. B. Simmons, and W. C. Dement, "Hemodynamics in sleepinduced apnea: studies during wakefulness and sleep," *Annals* of Internal Medicine, vol. 85, no. 6, pp. 714–719, 1976.
- [6] E. Weitzenblum, J. Krieger, M. Apprill et al., "Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome," *American Review of Respiratory Disease*, vol. 138, no. 2, pp. 345–349, 1988.
- [7] A. Chaouat, E. Weitzenblum, J. Krieger, M. Oswald, and R. Kessler, "Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients," *Chest*, vol. 109, no. 2, pp. 380–386, 1996.
- [8] B. M. Sanner, C. Doberauer, M. Konermann, A. Sturm, and W. Zidek, "Pulmonary hypertension in patients with obstructive sleep apnea syndrome," *Archives of Internal Medicine*, vol. 157, no. 21, pp. 2483–2487, 1997.
- [9] D. Sajkov, R. J. Cowie, A. T. Thornton, H. A. Espinoza, and R. D. McEvoy, "Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome," *American Journal of Respiratory and Critical Care Medicine*, vol. 149, no. 2, part 1, pp. 416–422, 1994.

- [10] E. Bady, A. Achkar, S. Pascal, E. Orvoen-Frija, and J.-P. Laaban, "Pulmonary arterial hypertension in patients with sleep apnoea syndrome," *Thorax*, vol. 55, no. 11, pp. 934–939, 2000.
- [11] O. A. Minai, B. Ricaurte, R. Kaw et al., "Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome," *The American Journal of Cardiology*, vol. 104, no. 9, pp. 1300–1306, 2009.
- [12] B. M. Sanner, M. Konermann, A. Sturm, H. J. Muller, and W. Zidek, "Right ventricular dysfunction in patients with obstructive sleep apnoea syndrome," *European Respiratory Journal*, vol. 10, no. 9, pp. 2079–2083, 1997.
- [13] F. Haddad, R. Doyle, D. J. Murphy, and S. A. Hunt, "Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure," *Circulation*, vol. 117, no. 13, pp. 1717–1731, 2008.
- [14] M. I. Burgess, N. Mogulkoc, R. J. Bright-Thomas, P. Bishop, J. J. Egan, and S. G. Ray, "Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease," *Journal of the American Society* of Echocardiography, vol. 15, no. 6, pp. 633–639, 2002.
- [15] P. Hanly, Z. Sasson, N. Zuberi, and M. Alderson, "Ventricular function in snorers and patients with obstructive sleep apnea," *Chest*, vol. 102, no. 1, pp. 100–105, 1992.
- [16] U. C. Guidry, L. A. Mendes, J. C. Evans et al., "Echocardiographic features of the right heart in sleep-disordered breathing: The Framingham Heart Study," *American Journal of Respiratory* and Critical Care Medicine, vol. 164, no. 6, pp. 933–938, 2001.
- [17] J. Verbraecken, C. Van de Heyning, M. Kerremans et al., "Echocardiographic and tissue doppler evaluation of cardiac function in obstructive sleep apnea before and after CPAP therapy," *Nederlandse vereniging voor Slaap - Waak Onderzoek*, vol. 16, pp. 129–132, 2005.
- [18] N. Dursunoğlu, D. Dursunoğlu, and M. Kılıç, "Impact of obstructive sleep apnea on right ventricular global function: Sleep apnea and myocardial performance index," *Respiration*, vol. 72, no. 3, pp. 278–284, 2005.
- [19] B. Shivalkar, C. van de Heyning, M. Kerremans et al., "Obstructive sleep apnea syndrome: more insights on structural and functional cardiac alterations, and the effects of treatment with continuous positive airway pressure," *Journal of the American College of Cardiology*, vol. 47, no. 7, pp. 1433–1439, 2006.
- [20] H. A. Kasikcioglu, L. Karasulu, Z. Tartan, E. Kasikcioglu, C. Cuhadaroglu, and N. Cam, "Occult cardiac dysfunction in patients with obstructive sleep apnea syndrome revealed by tissue Doppler imaging," *International Journal of Cardiology*, vol. 118, no. 2, pp. 203–205, 2007.
- [21] A. Romero-Corral, V. K. Somers, P. A. Pellikka et al., "Decreased right and left ventricular myocardial performance in obstructive sleep apnea," *Chest*, vol. 132, no. 6, pp. 1863–1870, 2007.
- [22] M. E. Otto, M. Belohlavek, A. Romero-Corral et al., "Comparison of Cardiac Structural and Functional Changes in Obese Otherwise Healthy Adults With Versus Without Obstructive Sleep Apnea," *American Journal of Cardiology*, vol. 99, no. 9, pp. 1298–1302, 2007.
- [23] Y. Tavil, A. Kanbay, N. Şen et al., "Comparison of right ventricular functions by tissue Doppler imaging in patients with obstructive sleep apnea syndrome with or without hypertension," *International Journal of Cardiovascular Imaging*, vol. 23, no. 4, pp. 469–477, 2007.
- [24] N. A. Bayram, B. Ciftci, H. Bayram et al., "Effects of continuous positive airway pressure therapy on right ventricular function

assessment by tissue Doppler imaging in patients with obstructive sleep apnea syndrome," *Echocardiography*, vol. 25, no. 10, pp. 1071–1078, 2008.

- [25] A. Kepez, E. Y. O. Niksarlioglu, T. Hazirolan et al., "Early myocardial functional alterations in patients with obstructive sleep apnea syndrome," *Echocardiography*, vol. 26, no. 4, pp. 388–396, 2009.
- [26] A. Tugcu, D. Guzel, O. Yildirimturk, and S. Aytekin, "Evaluation of right ventricular systolic and diastolic function in patients with newly diagnosed obstructive sleep apnea syndrome without hypertension," *Cardiology*, vol. 113, no. 3, pp. 184–192, 2009.
- [27] A. Tugcu, O. Yildirimtürk, Y. Tayyareci, C. Demiroglu, and S. Aytekin, "Evaluation of subclinical right ventricular dysfunction in obstructive sleep apnea patients using velocity vector imaging," *Circulation Journal*, vol. 74, no. 2, pp. 312–319, 2010.
- [28] S.-Q. Yang, L.-L. Han, X.-L. Dong et al., "Mal-effects of obstructive sleep apnea on the heart," *Sleep and Breathing*, vol. 16, no. 3, pp. 717–722, 2012.
- [29] R. E. Altekin, M. S. Karakas, A. Yanikoglu et al., "Determination of right ventricular dysfunction using the speckle tracking echocardiography method in patients with obstructive sleep apnea," *Cardiology Journal*, vol. 19, no. 2, pp. 130–139, 2012.
- [30] C. Hammerstingl, R. Schueler, M. Wiesen et al., "Effects of untreated obstructive sleep apnea on left and right ventricular myocardial function," *International Journal of Cardiology*, vol. 155, no. 3, pp. 465–469, 2012.
- [31] F. Öztuna, H. Gözaçan, G. Kiriş et al., "Effect of nasal continuous positive airway pressure on global right ventricular myocardial performance in patients with obstructive sleep apnea syndrome," *Turkish Journal of Medical Sciences*, vol. 43, no. 3, pp. 393–399, 2013.
- [32] Ö. Araz, E. Yilmazel Uçar, H. Değirmenci et al., "The correlation of ECHO findings of right cardiac pathologies with BNP, uric acid, and CRP in OSAS," *Turkish Journal of Medical Sciences*, vol. 44, no. 5, pp. 832–838, 2014.
- [33] A. Vitarelli, C. Terzano, M. Saponara et al., "Assessment of right ventricular function in obstructive sleep apnea syndrome and effects of continuous positive airway pressure therapy: a pilot study," *Canadian Journal of Cardiology*, vol. 31, no. 7, pp. 823– 831, 2015.
- [34] G. Ozkececi, S. S. Ulasli, O. Akci et al., "Assessment of pulmonary arterial stiffness in obstructive sleep apnea," *International Journal of Cardiovascular Imaging*, vol. 32, no. 5, pp. 799– 805, 2016.
- [35] I. H. Altiparmak, M. E. Erkus, M. Polat et al., "Evaluation of pulmonary artery stiffness in patients with obstructive sleep apnea syndrome," *Echocardiography*, vol. 33, no. 3, pp. 362–371, 2016.
- [36] J. Li, Z. Wang, Y. Li et al., "Assessment of regional right ventricular systolic function in patients with obstructive sleep apnea syndrome using velocity vector imaging," *Medicine (Baltimore)*, vol. 95, no. 37, Article ID e4788, 2016.
- [37] P. Dobrowolski, E. Florczak, A. Klisiewicz et al., "Pulmonary artery dilation indicates severe obstructive sleep apnea in patients with resistant hypertension: the resist-pol study," *Polskie Archiwum Medycyny Wewnetrznej*, vol. 126, no. 4, pp. 222– 229, 2016.
- [38] N.-W. Zhou, C.-Z. Pan, D.-H. Kong et al., "A novel method for sensitive determination of subclinical right ventricular systolic dysfunction in patients with obstructive sleep apnea," *The Clinical Respiratory Journal*, 2016.

- [39] A. D'Andrea, F. Martone, B. Liccardo et al., "Acute and chronic effects of noninvasive ventilation on left and right myocardial function in patients with obstructive sleep apnea syndrome: a speckle tracking echocardiographic study," *Echocardiography*, vol. 33, no. 8, pp. 1144–1155, 2016.
- [40] E. Grünig and A. J. Peacock, "Imaging the heart in pulmonary hypertension: an update," *European Respiratory Review*, vol. 24, no. 138, pp. 653–664, 2015.
- [41] A. Vonk Noordegraaf, F. Haddad, H. J. Bogaard, and P. M. Hassoun, "Noninvasive imaging in the assessment of the cardiopulmonary vascular unit," *Circulation*, vol. 131, no. 10, pp. 899–913, 2015.
- [42] L. G. Rudski, W. W. Lai, J. Afilalo et al., "Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography," *Journal of the American Society of Echocardiography*, vol. 23, quiz 786-8, no. 7, pp. 685–713, 2010.
- [43] T. Kasai and T. D. Bradley, "Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications," *Journal* of the American College of Cardiology, vol. 57, no. 2, pp. 119–127, 2011.
- [44] T. D. Bradley, R. Rutherford, R. F. Grossman et al., "Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome," *American Review of Respiratory Disease*, vol. 131, no. 6, pp. 835–839, 1985.
- [45] T. D. Bradley, M. J. Hall, S.-I. Ando, and J. S. Floras, "Hemodynamic effects of simulated obstructive apneas in humans with and without heart failure," *Chest*, vol. 119, no. 6, pp. 1827–1835, 2001.
- [46] A. Sokmen, G. Sokmen, G. Acar et al., "The impact of isolated obesity on right ventricular function in young adults," *Arquivos Brasileiros de Cardiologia*, vol. 101, no. 2, pp. 160–168, 2013.
- [47] C. Y. Wong, T. O'Moore-Sullivan, R. Leano, C. Hukins, C. Jenkins, and T. H. Marwick, "Association of subclinical right ventricular dysfunction with obesity," *Journal of the American College of Cardiology*, vol. 47, no. 3, pp. 611–616, 2006.